Department of Haematology, Peninsula Medical School, University of Plymouth, Plymouth, UK.
Department of Haematology, Oxford University Hospitals, Oxford, UK.
Hematol Oncol Clin North Am. 2020 Oct;34(5):923-939. doi: 10.1016/j.hoc.2020.06.008. Epub 2020 Aug 5.
In this review, we explore insights into the pathophysiology of Bruton tyrosine kinase inhibitor (BTKi) resistance in mantle cell lymphoma, and consider potential therapeutic targets. We review the possible clinical benefits of giving BTKis alongside other novel therapies, and evaluate clinical data for treatment strategies post BTKi progression that may help guide current practice. We conclude by considering future approaches, including the potential role of chimeric antigen receptor T-cell therapy.
在这篇综述中，我们探讨了套细胞淋巴瘤中布鲁顿酪氨酸激酶抑制剂 (BTKi) 耐药的病理生理学见解，并考虑了潜在的治疗靶点。我们回顾了在给予 BTKi 的同时联合其他新型疗法的可能临床获益，并评估了 BTKi 进展后可能有助于指导当前实践的治疗策略的临床数据。最后，我们考虑了未来的方法，包括嵌合抗原受体 T 细胞疗法的潜在作用。
